Belviq lorcaserin: Phase IV data

Top-line data from a double-blind, U.S. Phase IV trial in 238 overweight and obese adults showed that the combination of twice-daily 10 mg lorcaserin plus once- or twice-daily 15 mg immediate-release phentermine was not associated with an increase in the proportion of patients reporting >=1 of 9 common potential serotonergic adverse events from baseline to week 12, the primary endpoint, vs. lorcaserin alone. Patients also received standardized weight-loss counseling. Data were presented at the ObesityWeek meeting in Boston. FDA approved lorcaserin as Belviq in 2012 to treat obesity. ...